Monday, January 30, 2012

Health News: [cancer]


Novara fires coach Tesser, 12th Serie A change
The News-Times Mon, 30 Jan 2012 10:02 AM PST
Mondonico has not coached in the top division since being fired by Fiorentina seven years ago. He quit as coach of Serie B Albinoleffe in the offseason to focus on battling cancer.

Helping blaze a new trail
Edwardsville Intelligencer Mon, 30 Jan 2012 10:01 AM PST
Allen Cassens sat and talked about cancer research. Not the kind that starts in a laboratory and eventually finds its way into a doctor's practice. He spoke of research that the brightest Ph.Ds in med

Press Release
PharmiWeb Mon, 30 Jan 2012 10:00 AM PST
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that ErivedgeTM (vismodegib) capsule was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with a type of skin cancer, called basal cell carcinoma (BCC), that has spread to other parts of the body or that has come back after surgery or that their healthcare provider decides ...

FDA approves Roche skin cancer drug Erivedge
Detroit Free Press Mon, 30 Jan 2012 09:58 AM PST
Federal regulators on Monday approved a pill that treats the most common type of skin cancer, basal cell carcinoma.

4-week vaccination regimen knocks out early breast cancer tumors, Penn researchers report
EurekAlert! Mon, 30 Jan 2012 09:57 AM PST
( University of Pennsylvania School of Medicine ) Researchers at the Perelman School of Medicine at the University of Pennsylvania report that a short course of vaccination with an anti-HER2 dendritic cell vaccine made partly from the patient's own cells triggers a complete tumor eradication in nearly 20 percent of women with ductal carcinoma in situ, an early breast cancer.

FDA approves Roche skin cancer drug
Reuters via Yahoo! Canada News Mon, 30 Jan 2012 09:57 AM PST
(Reuters) - U.S. health regulators on Monday approved Roche's pill to treat an advanced form of the most common form of skin cancer, known as basal cell carcinoma. The drug, Erivedge, which was co-developed by Curis Inc, was given a green light by the Food and Drug Administration more than a month ahead of the expected March 8 decision date. It was approved for use by adults whose cancer cannot ...

Cancer Teen Suspended for Locks of Love
ABC News Mon, 30 Jan 2012 09:56 AM PST
Seventeen-year-old J.T. Gaskins was suspended from Madison Academy in Michigan for having hair that did not comply with the school's rules for how long boys can grow their hair. But Gaskins is sporting the shaggy hairdo for a very specific reasonĂ¢€"as a leukemia survivor, he is determined to donate his hair to Locks of Love.

Quitman Commission vice-chair passes
Eufaula Tribune Mon, 30 Jan 2012 09:56 AM PST
Quitman Commission vice-chair passes David McMiller, vice-chair of the Quitman County Commission, passed away Sunday, Jan. 29, following a lengthy battle with cancer, according to commission chair Richard Morris.

UPDATE 2-U.S. FDA approves Roche skin cancer drug
Reuters - UK Focus via Yahoo! UK & Ireland Finance Mon, 30 Jan 2012 09:54 AM PST
* Drug treats advanced basal cell carcinoma * Erivedge a pill taken once daily * Co-developer Curis to receive royalty on sales (Adds cost of treatment, share price) Jan 30 (Reuters) - U.S. health regulators ...

FDA approves Genentech's Erivedge, first drug to treat advanced form of most common type of skin cancer
Contra Costa Times Mon, 30 Jan 2012 09:54 AM PST
Federal regulators on Monday approved a pill that treats the most common type of skin cancer, basal cell carcinoma.




See more health stories that match my keyword
Visit Yahoo! Health


You received this email because you subscribed to Yahoo! Alerts. Use this link to unsubscribe from this alert. To change your communications preferences for other Yahoo! business lines, please visit your Marketing Preferences. To learn more about Yahoo!'s use of personal information, including the use of web beacons in HTML-based email, please read our Privacy Policy. Yahoo! is located at 701 First Avenue, Sunnyvale, CA 94089.
\"\"

No comments:

Post a Comment